subsidiaries

Gome Fin Tech Announced Annual Results of 2023

Source Node:
Time Stamp: April 1, 2024 1:23 PM - Modified On: April 1, 2024 - Published By:
Source Cluster:
Republished By Plato

  Commercial Factoring Progresses Despite Stability Diversified Businesses Ready for Development HONG KONG, Mar 29, 2024 - (ACN Newswire) - Gome Finance Technology Co., Ltd.(Stock Code:628.HK,“Gome Fin Tech”or “the Company”,with its subsidiaries,the“Group”), announced its audited annual results for the year ended 31 December, 2023 (the “Reporting Period”). In 2023, the global geopolitical risks are frequent, the lack of economic recovery momentum and the widening trend of differentiation among countries are highlighted, and the risk spillover from European and US banks under the global high interest rate environment also casts a

Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries

Source Node:
Time Stamp: February 2, 2024 2:30 PM - Modified On: February 2, 2024 - Published By:
Source Cluster:
Republished By Plato

  New York, Feb 2, 2024 - (Plato Data)- Fortress Biotech (Fortress Bio), a unique biotech company led by industry veteran Dr. Lindsay Rosenwald, focused on identifying, in-licensing and developing high-potential marketed drugs and development-stage drug candidates in-house and through its subsidiary partner companies, has announced multiple new milestones to start 2024 with a bang. Avenue Therapeutics Finalizes Phase 3 Study for IV Tramadol with FDA Avenue Therapeutics, a subsidiary of Fortress Bio, has reached a significant milestone in its quest to introduce new therapies for neurologic diseases. The company